RE:RE:RE:Volume 131,400 in Canada | TTM Operating Cash flows (OCF) | $6,317,000 |
| TTM cash flow yield / Enterprise Value | 16.1% |
That's cheap!
"Companies working on drug or nutraceutical development can never be sure that their formulation will become a commercial success." The thing about CZO is the yeast beta glucan market already exists. It may be more of a manufacturing scale-up problem for CZO. CZO's product is multi-fold more stimulatory than competitors. It could require a fraction of the dose for the same result. Cost savings? Alginate is also already used for delivery. PGX-Alginate has 90X more surface area and can be better loaded. Co10 is an established market. The formulation risk may be minimal. Scaling it up cost-effectively may be the biggest risk.There's some diversification of opportunity to help spread risk. CZO is the only company in the world that can produce natural avenanthramide at scale.
laurencelefou wrote: Companies working on drug or nutraceutical development can never be sure that their formulation will become a commercial success. Investors must consider that possibility when deciding on whether or not to invest in a company with a pipeline that may or may not become a profitable venture. If one of Ceapro’s potential formulation is successfully marketed, then the share price will react positively. Because of its strong balance sheet and very profitable operating business, if Ceapro’s pipeline turns out to be a flop, the share price will remain stagnant.
Ceapro offers little downside risk.
| | Trailing |
| | Twelve-months |
| Revenue | $19,079,000 |
| | |
| Net income | $6,627,000 |
| | |
| Cash generated from operations | $6,317,000 |
| | |
| Investing activities | ($523,000) |
| Financing activities | ($295,000) |
| | |
| Share price (2022-12-29) | .60 |
| | |
| Number of outstanding shares | 78,218,177 |
| Number of stock options | 2,347,999 |
| Total number of shares | 80,566,176 |
| Market cap | $48,339,706 |
| Cash | $12,910,069 |
| Cash from options | $1,129,480 |
| Debt | |
| Enterprise value | $34,300,157 |
| TTM Operating Cash flows (OCF) | $6,317,000 |
| TTM cash flow yield / Enterprise Value | 16.1% |
| Enterprise Value / OCF | 6.2 |